Daiwa Securities Group Inc. Has $18.75 Million Stock Position in Becton, Dickinson and Company $BDX

Daiwa Securities Group Inc. grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 27.2% in the fourth quarter, HoldingsChannel reports. The fund owned 96,592 shares of the medical instruments supplier’s stock after acquiring an additional 20,651 shares during the period. Daiwa Securities Group Inc.’s holdings in Becton, Dickinson and Company were worth $18,746,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BDX. Crux Wealth Advisors raised its stake in Becton, Dickinson and Company by 0.8% in the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after acquiring an additional 49 shares during the period. Larson Financial Group LLC raised its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after acquiring an additional 53 shares during the period. Camelot Portfolios LLC raised its stake in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC raised its stake in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after acquiring an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp raised its stake in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after acquiring an additional 57 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.2%

BDX stock opened at $151.33 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $41.70 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 10.59 and a beta of 0.22. The business’s fifty day moving average price is $150.72 and its two-hundred day moving average price is $175.54. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,913 shares of company stock worth $426,806. 0.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Argus lowered their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. Finally, Piper Sandler lowered their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $183.64.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.